Prof. Julia C. Tchou

University of Pennsylvania School of Medicine, USA

Email: [email protected]

Qualifications

1989 Ph.D., State University of New York

1982 B.Sc., College of Mount Saint Vincent

Publications (selected)

1. De Jesus, E., Woo, S., Krouse, R. S., et al. (2026). A community based participatory research approach to evaluate barriers and facilitators for behavioral weight loss intervention implementation in a predominantly black community. Supportive Care in Cancer, 34(4), Article 406.
2. Liu, S., Guruprasad, P., Ramasubramanian, R., et al. (2026). β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer. Cell, 189(6), 1701–1716.
3. Tchou, J., Nayak, A., Xu, H. N., et al. (2026). A single preoperative pembrolizumab dose plus a single subablative radiotherapy fraction (7 Gy) elicits anti-tumor immune response and increases stromal tumor infiltrating lymphocytes in triple negative breast cancer: a phase 1b/2 study. Clinical Cancer Research, 32(Suppl 4), Meeting Abstract PS4-07-15.
4. Szeto, J. J., Kim, H., Shen, C. Z., et al. (2025). Reducing misclassification of medical waste: nudging stakeholders to reduce waste misclassification in a novel simulated operating room built environment. Perioperative Medicine, 14(1), Article 123.
5. Tortorello, G. N., Shafique, N., De Jesus, E. M., et al. (2026). Sentinel Lymph Node Biopsy in Low-Risk Breast Cancer in Patients ≥ 70 Years: How Wisely are We Choosing?. Annals of Surgical Oncology, 33(2), 1212–1220.
6. Van Hassel, J., Dimitroff, K., Yau, C., et al. (2025). ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial. Annals of Surgical Oncology, 32(11), 8127–8128.
7. Mukhtar, R. A., Dimitroff, K., Yau, C., et al. (2025). ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial. Annals of Surgical Oncology, 32(11), 8254–8255.
8. Van Hassel, J., Dimitroff, K., Yau, C., et al. (2025). Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial. Annals of Surgical Oncology, 32(11), 8113–8126.
9. Kaur, M., Dimitroff, K., Boughey, J. C., et al. (2025). ASO Visual Abstract: Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Annals of Surgical Oncology, 32(11), 8222–8223.
10. Mukhtar, R. A., Dimitroff, K., Yau, C., et al. (2025). Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial. Annals of Surgical Oncology, 32(11), 8243–8253.
11. Kaur, M., Dimitroff, K., Boughey, J. C., et al. (2025). Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Annals of Surgical Oncology, 32(11), 8211–8219.
12. Berkowitz, C., DeJesus, E., Perez-Rojas, S., et al. (2025). Navigating Chemotherapy Decisions in Early-Stage Breast Cancer: The Role of Oncotype DX Recurrence Scores in a National Cohort. Annals of Surgical Oncology, 32(Suppl 2), 511.
13. DeJesus, E., Berkowitz, C., Perez-Rojas, S., et al. (2025). Omission of Lymph Node Sampling in cT1cN0 Patients with Breast Cancer Undergoing Mastectomy: Implications for SOUND trial implementation. Annals of Surgical Oncology, 32(Suppl 2), 768–769.
14. Kaur, M., Dimitroff, K., Boughey, J., et al. (2025). Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Annals of Surgical Oncology, 32(Suppl 2), 346–348.
15. Mukhtar, R., Dimitroff, K., Yau, C., et al. (2025). Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial. Annals of Surgical Oncology, 32(Suppl 2), 325–326.
16. Van Hassel, J., Dimitroff, K., Yau, C., et al. (2025). Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial. Annals of Surgical Oncology, 32(Suppl 2), 320–322.
17. Yoon, I. C., Perez-Rojas, S., Ancha, B., et al. (2025). ASO Visual Abstract: Association of Neighborhood Deprivation with Stage at Diagnosis and Treatment Delay for Breast Cancer in Philadelphia. Annals of Surgical Oncology, 32(8), 5585–5586.
18. Kulkarni, S., Greene, G., Blanco, L., et al. (2025). The Promise study: A presurgical randomized clinical trial of CE/BZA vs placebo in postmenopausal women with ductal carcinoma in situ. Journal of Clinical Oncology, 43(16_suppl), Article 512.
19. Mukhtar, R., Dimitroff, K., Yau, C., et al. (2025). Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial. Journal of Clinical Oncology, 43(16_suppl), 504.
20. Tchou, J., Goldbach, M., Nayak, A., & Shah, P. D. (2025). Impact of HER2 low status on pathologic response after neoadjuvant chemotherapy in TNBC: A large scale retrospective cohort study. Journal of Clinical Oncology, 43(16_suppl), 571.

Profile Details
https://www.pennmedicine.org/providers/julia-tchou
https://scholar.google.com/citations?user=ZvVZP_oAAAAJ&hl=en
https://www.researchgate.net/scientific-contributions/Julia-C-Tchou-2148542196

WOS ResearcherID: GWL-3709-2022